Htg Molecular Diagnostics, Inc.

John Wayne Cancer Institute

Tom Vasicek

Bruce Seligmann

Dave S B Hoon

Hui Wang

Debrah Thompson

Krishna Maddula

Bj Kerns

Christopher Roberts

Debra A Gordon

Zhenquiang Lu

B J Kerns

Dave SB Hoon

Justin Brown

Disclosed are methods for determining whether a melanocyte-containing sample (such as a nevus or other pigmented lesion) is benign or a primary melanoma. These methods can include detecting (at the molecular level, e.g., mRNA, miRNA, or protein) the expression of at least two disclosed genes in a biological sample obtained from a subject. Also provided are arrays and kits that can be used with the methods.

Molecular malignancy in melanocytic lesions

The present disclosure provides an improvement to quantitative Nuclease Protection Assay (qNPA) and quantitative Nuclease Protection Sequencing (qNPS) methods. The disclosed methods use nuclease protection probes (NPPs) that include 5'-end and/or 3-end flanking sequences, which provide a universal hybridization and/or amplification sequence. The disclosed methods can be used to sequence or detect target nucleic acid molecules, such as those present in fixed or insoluble samples.

Quantitative nuclease protection assay (QNPA) and sequencing (QNPS) improvements

Growing community of inventors

Minneapolis, MN, United States of America

Tom Vasicek